Key features and details
- Mouse monoclonal [M148] to CD41
- Suitable for: Flow Cyt, ICC/IF, IP, IHC-Fr
- Reacts with: Human
- Isotype: IgG2a
Product nameAnti-CD41 antibody [M148]
See all CD41 primary antibodies
DescriptionMouse monoclonal [M148] to CD41
Tested applicationsSuitable for: Flow Cyt, ICC/IF, IP, IHC-Frmore details
Species reactivityReacts with: Human
Tissue, cells or virus corresponding to Human CD41. Homogenized human medulloblastoma tissue.
Database link: P08514
- Flow Cyt: HEL92.1.7 cells.
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact firstname.lastname@example.org.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium azide
Constituents: PBS, 6.97% L-Arginine
Concentration information loading...
PurityProtein G purified
Light chain typekappa
Our Abpromise guarantee covers the use of ab11024 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use a concentration of 0.1 µg/ml.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
|ICC/IF||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
FunctionIntegrin alpha-IIb/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. It recognizes the sequence R-G-D in a wide array of ligands. It recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial cell surface.
Tissue specificityIsoform 1 and isoform 2 were identified in platelets and megakaryocytes, but not in reticulocytes or in Jurkat and U937 white blood cell line. Isoform 3 is expressed by leukemia, prostate adenocarcinoma and melanoma cells but not by platelets or normal prostate or breast epithelial cells.
Involvement in diseaseDefects in ITGA2B are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. It is an autosomal recessive disorder characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors.
Sequence similaritiesBelongs to the integrin alpha chain family.
Contains 7 FG-GAP repeats.
- Information by UniProt
- antigen CD41 antibody
- BDPLT16 antibody
- BDPLT2 antibody
Overlay histograms showing left HEL92.1.7 cells and right Jurkat cells stained with ab11024 (red line). The cells were incubated in 1x PBS / 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (ab11024) (1x106 in 100µl at 0.1µg/ml) for 30 min on ice.
The secondary antibody Goat anti-mouse IgG H&L (Alexa Fluor ® 488, pre-adsorbed) (ab150177)was used at 1/2000 dilution for 30 min at 4°C. Isotype control antibody (black line) was mouse IgG1κ (ab170190) used at the same concentration and conditions as the primary antibody. Unlabelled sample (blue line) was also used as a control.
Acquisition of >5,000 events were collected using a 50 mW Blue laser (488nm) and 530/30 bandpass filter. Events were gated on viable single cells.
IHC-Fr image of C41 staining on human blood film using ab11024 (1:1000). The sample was fixed using paraformaldehyde and permeabilized using 0.1% TritonX in 0.1% PBS. The slides were then blocked with 10% Donkey Serum for 1 hr at 24°C. ab11024 was diluted 1:100 using 0.1% TritonX with 0.1x PBS- 10% Donkeys and slides were incubated with the primary antibody for 4 hours at 24°C. The secondary antibody used was Donkey Polyclonal to rabbit IgG conjugated to Alexa Fuor 568 (1:1000)
ICC/IF image of ab11024 staining of human platelet cells. The sections were incubated in 10% serum to block non-specific protein-protein interactions and in 0.2% triton X to permeabilise the cells. The sections were then incubated with ab11024 (1:400) for one hour at 20°C, followed by alexa 488 conjugated secondary antibody (green). Platelets were counterstained with rhodamine phalloidin to outline the cellular cytoskeleton (red).
Overlay histogram showing HL60 cells stained with ab11024 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab11024, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive result in 80% methanol (5 min) fixed HL60 cells used under the same conditions.
Please note that Abcam do not have any data for use of this antibody on non-fixed cells. We welcome any customer feedback.
ab11024 has been referenced in 8 publications.
- Rambøl MH et al. Recellularization of Decellularized Venous Grafts Using Peripheral Blood: A Critical Evaluation. EBioMedicine 32:215-222 (2018). IHC-Fr ; Human . PubMed: 29779699
- Dhenge A et al. Arachidonic acid and Docosahexanoic acid enhance platelet formation from human apheresis-derived CD34+ cells. Cell Cycle 16:979-990 (2017). PubMed: 28388313
- Lohrke J et al. 18F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. J Nucl Med 58:1094-1099 (2017). PubMed: 28302764
- Zhao H et al. Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia. Mol Cancer Ther 16:1877-1886 (2017). PubMed: 28655784
- Schunke KJ et al. A novel atherothrombotic model of ischemic stroke induced by injection of collagen into the cerebral vasculature. J Neurosci Methods 239:65-74 (2015). PubMed: 25314906
- Finnegan S et al. Synovial membrane protein expression differs between juvenile idiopathic arthritis subtypes in early disease. Arthritis Res Ther 16:R8 (2014). IHC-Fr ; Human . PubMed: 24410838
- Alonso-Orgaz S et al. Proteomic characterization of human coronary thrombus in patients with ST-segment elevation acute myocardial infarction. J Proteomics 109C:368-381 (2014). IHC-P ; Human . PubMed: 25065646
- Jones D et al. A monoclonal antibody binding to human medulloblastoma cells and to the platelet glycoprotein IIB-IIIA complex. Br J Haematol 57:621-31 (1984). PubMed: 6234927